Effects of Photobiomodulation Therapy Combined With Static Magnetic Field in CrossFit® Athletes
- Conditions
- Muscle Strength
- Interventions
- Device: Effective PBMT/sMFDevice: Placebo PBMT/sMF
- Registration Number
- NCT04349085
- Lead Sponsor
- University of Nove de Julho
- Brief Summary
Crossfit® is a method of strength training and fitness built on functional movements, constantly varied and executed at high intensity. Competitions such as the Crossfit® involve physically demanding activities, which in addition to being performed at high intensity also use great measures of aerobic capacity related with performance. These characteristics cause metabolic and muscular stress, as well as a decrease in physical performance. The demand for intensity is the cause of concern regarding the practice of Crossfit® and the risk of injuries. Studies using photobiomodulation therapy combined with static magnetic fields (PBMT/sMF) to delay fatigue and increase performance have obtained positive results in different types of exercise and application times. However, there are no studies investigating the effects of PBMT/sMF in training with similar characteristics as Crossfit®. Therefore, the aim of this project is to verify the effects of PBMT/sMF on performance and muscle recovery of Crossfit® athletes at different times of application (pre workout of the day \[WOD\] and/or post WOD) in order to determine the best way to use the therapy.
- Detailed Description
To achieve the proposed objective it will be performed a randomized, crossover, triple-blind (volunteers, outcome assessors and therapists), placebo-controlled trial.
Twelve volunteers will be allocated to four interventions/situation. The order of the interventions/situations will be randomized.
The volunteers will be treated by a blinded therapist.
The outcomes will be obtained at baseline (prior to WOD), and 1 hour, 24 and 48 hours after WOD. Except for the ratings of perceived exertion that will be obtained at baseline, after WOD, and 1 hour, 24 and 48 hours after WOD. In addition, for the functional analysis the data will be collected at baseline, after applied intervention, and 1 hour, 24 and 48 hours after WOD. The data will be collected by a blinded assessor.
The WOD will be consisted in finish as quickly as possible a sequence of three exercises (Calories in Assault AirBike®, Hang Squat Clean and Box Jump Over), in a well-known series model for the athletes, without rest.
The investigators will analyze: ratings of perceived exertion; activity of creatine kinase (CK); levels of the cytokine Interleukin-6 (IL-6), and maximum number of free squat reps in 1 minute.
Statistical analysis:
All data will be analyzed both in their absolute values and in relation to their percentage variation from the values obtained in the pre-WOD (baseline) assessments. The results obtained will be tested for normality using the Kolmogorov-Smirnov test. If data show normal distribution, the ANOVA test (one or two way depending on the outcome analyzed) with post-hoc Bonferroni will be used. The level of statistical significance will be p\<0.05.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Male
- Target Recruitment
- 12
- Crossfit® amateur male athletes;
- who did not present a history of musculoskeletal injury in the regions of the hips, knees and calves in the month preceding the study;
- who were not using pharmacological agents;
- athletes should have been practicing the sport for at least 1 year;
- voluntarily commit to participate in all stages.
- who presented musculoskeletal or joint injuries during data collection.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- CROSSOVER
- Arm && Interventions
Group Intervention Description Effective PBMT/sMF before WOD and Placebo PBMT/sMF after WOD Effective PBMT/sMF PBMT/sMF will be applied in two steps: effective PBMT/sMF will be applied before the WOD and placebo PBMT/sMF will be applied after the WOD. Effective PBMT/sMF before WOD and Placebo PBMT/sMF after WOD Placebo PBMT/sMF PBMT/sMF will be applied in two steps: effective PBMT/sMF will be applied before the WOD and placebo PBMT/sMF will be applied after the WOD. Placebo PBMT/sMF before WOD and Effective PBMT/sMF after WOD Effective PBMT/sMF PBMT/sMF will be applied in two steps: placebo PBMT/sMF will be applied before the WOD and effective PBMT/sMF will be applied after the WOD. Effective PBMT/sMF before WOD and Effective PBMT/sMF after WOD Effective PBMT/sMF PBMT/sMF will be applied in two steps: effective PBMT/sMF will be applied before the WOD and effective PBMT/sMF will be applied after the WOD. Placebo PBMT/sMF before WOD and Effective PBMT/sMF after WOD Placebo PBMT/sMF PBMT/sMF will be applied in two steps: placebo PBMT/sMF will be applied before the WOD and effective PBMT/sMF will be applied after the WOD. Placebo PBMT/sMF before WOD and Placebo PBMT/sMF after WOD. Placebo PBMT/sMF PBMT/sMF will be applied in two steps: placebo PBMT/sMF will be applied before the WOD and placebo PBMT/sMF will be applied after the WOD.
- Primary Outcome Measures
Name Time Method Change in functional capacity 1 minute post-treatment, 1hour, 24 hours and 48 hours after WOD (workout of the day). The functional capacity will be measured by a maximum number of free squat repetitions within 1 minute.
- Secondary Outcome Measures
Name Time Method Perception of exercise intensity 1 minute after WOD, 1 minute post-treatment, 1 hour, 24 hours and 48 hours after WOD (workout of the day). The perception of exercise intensity will be measured by a 0-100 Ratings of Perceived Exertion Scale: in this scale lower score, means lower degree of fatigue and higher score, means higher degree of fatigue.
Activity of creatine kinase (CK) 1 hour, 24 hours and 48 hours after WOD (workout of the day). The activity of CK will be analyzed by spectrophotometry and using specific reagent kits from the blood samples collected.
Levels of interleukin-6 (IL-6) 1 hour, 24 hours and 48 hours after WOD (workout of the day). The levels of interleukin-6 will be analyzed by enzyme-linked immunosorbent assay (ELISA) and using specific reagent kits from the blood samples collected.
Trial Locations
- Locations (1)
Laboratory of Phototherapy and Innovative Technologies in Health
🇧🇷São Paulo, Brazil